Literature DB >> 19321449

TIF1beta/KAP-1 is a coactivator of the orphan nuclear receptor NGFI-B/Nur77.

Juliette Rambaud1, Julien Desroches, Aurélio Balsalobre, Jacques Drouin.   

Abstract

In efforts to define mechanisms of transcriptional activation by the orphan nuclear receptor NGFI-B (Nur77), we identified TIF1beta by mass spectrometry within a nuclear protein complex containing NGFI-B. TIF1beta, also known as KAP-1 (KRAB domain-associated protein) or KRIP-1, acts as a transcriptional corepressor for many transcription factors, in particular for the Krüppel-associated box domain-containing zinc finger transcription factors. TIF1beta is also an intrinsic component of two chromatin remodeling and histone deacetylase complexes, the N-CoR1 and nucleosome remodeling and deacetylation complexes. In contrast to these activities, we report that TIF1beta is a coactivator of NGFI-B and that it is as potent as the SRC coactivators in this context. Using pull-down assays and immunoprecipitation, we showed that TIF1beta interacts directly with NGFI-B and with other Nur family members. NGFI-B is an important mediator of hypothalamic corticotropin-releasing hormone (CRH) activation of proopiomelanocortin (POMC) transcription, and TIF1beta enhances transcription mediated through the NGFI-B target, the Nur response element (NurRE). The NurRE binds Nur factor dimers and is responsive to signaling pathways. In keeping with the role of NGFI-B as mediator of CRH signaling, we found that TIF1beta is recruited to the POMC promoter following CRH stimulation and that TIF1beta potentiates CRH and protein kinase A signaling through the NurRE; it acts synergistically with the SRC2 coactivator. However, the actions of TIF1beta and SRC2 were mapped to different NGFI-B AF-1 subdomains. Taken together, these results indicate that TIF1beta is an important coactivator of NGFI-B-dependent transcription.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321449      PMCID: PMC2682863          DOI: 10.1074/jbc.M809023200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor.

Authors:  Christine Martens; Steve Bilodeau; Mario Maira; Yves Gauthier; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2004-12-09

2.  Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

Authors:  Steve Bilodeau; Sophie Vallette-Kasic; Yves Gauthier; Dominique Figarella-Branger; Thierry Brue; France Berthelet; André Lacroix; Dalia Batista; Constantine Stratakis; Jeanette Hanson; Björn Meij; Jacques Drouin
Journal:  Genes Dev       Date:  2006-10-15       Impact factor: 11.361

3.  Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness.

Authors:  Eric Batsché; Julien Desroches; Steve Bilodeau; Yves Gauthier; Jacques Drouin
Journal:  J Biol Chem       Date:  2005-03-14       Impact factor: 5.157

4.  Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family.

Authors:  A L Nielsen; J A Ortiz; J You; M Oulad-Abdelghani; R Khechumian; A Gansmuller; P Chambon; R Losson
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

5.  Two novel Krüppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 (TIF1beta/KRIP-1).

Authors:  Y Agata; E Matsuda; A Shimizu
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

6.  A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1.

Authors:  C Underhill; M S Qutob; S P Yee; J Torchia
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

7.  Sumoylation of the transcriptional intermediary factor 1beta (TIF1beta), the Co-repressor of the KRAB Multifinger proteins, is required for its transcriptional activity and is modulated by the KRAB domain.

Authors:  Xavier H Mascle; Delphine Germain-Desprez; Phuong Huynh; Patricia Estephan; Muriel Aubry
Journal:  J Biol Chem       Date:  2007-02-12       Impact factor: 5.157

8.  TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids.

Authors:  Konstantin Khetchoumian; Marius Teletin; Manuel Mark; Thierry Lerouge; Margarita Cerviño; Mustapha Oulad-Abdelghani; Pierre Chambon; Régine Losson
Journal:  J Biol Chem       Date:  2004-08-20       Impact factor: 5.157

9.  Conserved interaction between distinct Krüppel-associated box domains and the transcriptional intermediary factor 1 beta.

Authors:  M Abrink; J A Ortiz; C Mark; C Sanchez; C Looman; L Hellman; P Chambon; R Losson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development.

Authors:  F Cammas; M Mark; P Dollé; A Dierich; P Chambon; R Losson
Journal:  Development       Date:  2000-07       Impact factor: 6.868

View more
  33 in total

1.  FHL2 protein is a novel co-repressor of nuclear receptor Nur77.

Authors:  Kondababu Kurakula; Erik van der Wal; Dirk Geerts; Claudia M van Tiel; Carlie J M de Vries
Journal:  J Biol Chem       Date:  2011-11-02       Impact factor: 5.157

2.  Meeting report: nuclear receptors: transcription factors and drug targets connecting basic research with translational medicine.

Authors:  Jan Tuckermann; William Bourguet; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2010-06-02

3.  The TRIMming on an erythroid repressor complex.

Authors:  Margaret H Baron
Journal:  Blood       Date:  2013-11-28       Impact factor: 22.113

4.  Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.

Authors:  Monique G P van der Wijst; Christian Huisman; Archibold Mposhi; Gerard Roelfes; Marianne G Rots
Journal:  Mol Oncol       Date:  2015-03-19       Impact factor: 6.603

5.  TRIM28 mediates chromatin modifications at the TCRα enhancer and regulates the development of T and natural killer T cells.

Authors:  Xiao-Fei Zhou; Jiayi Yu; Mikyoung Chang; Minying Zhang; Dapeng Zhou; Florence Cammas; Shao-Cong Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

6.  Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.

Authors:  Shuaiying Cui; Katarzyna E Kolodziej; Naoshi Obara; Alexandra Amaral-Psarris; Jeroen Demmers; Lihong Shi; James Douglas Engel; Frank Grosveld; John Strouboulis; Osamu Tanabe
Journal:  Mol Cell Biol       Date:  2011-06-13       Impact factor: 4.272

7.  TRIM28 as an independent prognostic marker plays critical roles in glioma progression.

Authors:  Zeng-Xin Qi; Jia-Jun Cai; Ling-Chao Chen; Qi Yue; Yan Gong; Yu Yao; Ying Mao
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

Review 8.  Deconstructing repression: evolving models of co-repressor action.

Authors:  Valentina Perissi; Kristen Jepsen; Christopher K Glass; Michael G Rosenfeld
Journal:  Nat Rev Genet       Date:  2010-02       Impact factor: 53.242

9.  Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells.

Authors:  Syng-Ook Lee; Xi Li; Erik Hedrick; Un-Ho Jin; Ronald B Tjalkens; Donald S Backos; Li Li; Yi Zhang; Qiao Wu; Stephen Safe
Journal:  Mol Endocrinol       Date:  2014-08-06

10.  Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.

Authors:  Lu Chen; Dung-Tsa Chen; Courtney Kurtyka; Bhupendra Rawal; William J Fulp; Eric B Haura; W Douglas Cress
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.